Table 1.

Baseline HPV16 or HPV18 DNA load by characteristics of study subjects

	Log10 HPV16 E7 copies per 1 nanogram of cellular DNA			Log10 HPV18 E7 copies per 1 nanogram of cellular DNA
Variables	No.	Mean (SD)	P-value	No.	Mean (SD)	P-value
Age at study entry (years)
18–24	467	2.86 (1.33)	0.09	188	3.87 (1.58)	0.75
≥25	274	2.69 (1.36)		101	3.80 (1.76)
Race a
White	535	2.87 (1.31)	0.03	175	3.86 (1.66)	0.87
Nonwhite	201	2.62 (1.41)		113	3.82 (1.63)
Current use of hormonal contraceptives b
No	372	2.76 (1.42)	0.42	153	3.90 (1.79)	0.56
Yes	363	2.84 (1.26)		134	3.78 (1.47)
No. of life time male sex partners c
0–5	363	2.80 (1.38)	0.93	143	3.81 (1.60)	0.68
≥6	367	2.79 (1.32)		141	3.89 (1.69)
Current smoking
No	408	2.68 (1.33)	0.01	174	3.67 (1.61)	0.03
Yes	333	2.94 (1.34)		115	4.11 (1.67)
Coinfection with other HPV types
No	218	2.93 (1.31)	0.09	72	4.34 (1.63)	<0.001
Yes	523	2.74 (1.35)		217	3.68 (1.62)
HPV variant d
European	572	2.97 (1.21)	0.41	107	4.26 (1.38)	0.26
Non-European	130	2.88 (1.18)		144	4.05 (1.52)
Cytology at enrollment e
Within normal limits	140	1.76 (1.31)	<0.001	58	2.79 (1.72)	<0.001
ASC-US	208	2.76 (1.24)		81	3.88 (1.48)
LSIL	248	3.10 (1.26)		118	4.19 (1.54)
HSIL	140	3.39 (1.03)		32	4.38 (1.47)

^aNOTE. Excluded were 5 HPV16-positive women and one HPV18-positive woman who did not provide race information. A category of nonwhite includes African American, American Indian/Alaskan, or Asian/Pacific Islander women.

^bExcluded were 6 HPV16-positive women and 2 HPV18-positive women who did not provide information on use of hormonal contraceptives.

^cExcluded was 11 HPV16-positive woman and 5 HPV18-positive women who did not provide information of number of lifetime sex partners.

^dExcluded were 39 HPV16-positive women and 38 HPV18-positive whose enrollment samples were insufficient for variant characterization.

^eExcluded were 5 HPV16-positive women whose enrollment samples were inadequate for cytologic diagnosis.